Particle.news
Download on the App Store
9 ARTICLES
·
2d ago

Hims & Hers Shares Drop on Weak Q2 Guidance Despite Strong Q1 Results

The telehealth company posted a robust Q1 earnings beat but faces investor concerns over softer Q2 forecasts and the transition from compounded to branded semaglutide offerings.

Image
Image
Image
Image

Overview

  • Hims & Hers reported Q1 earnings of $0.20 per share and $586 million in revenue, significantly exceeding analyst expectations of $0.12 EPS and $538.6 million in revenue.
  • The company provided Q2 revenue guidance of $530–$550 million, falling short of the $564 million forecasted by analysts, marking its first projected quarter-over-quarter revenue decline since going public.
  • Subscriber growth rose 38% year-over-year to 2.37 million, with more than half on personalized medication regimens, though the total fell below analyst expectations of 2.42 million.
  • Hims & Hers is preparing for the May 22 FDA-mandated end of compounded semaglutide sales, transitioning to branded semaglutide through a partnership with Novo Nordisk.
  • The company appointed former Amazon executive Nader Kabbani as COO to support its growth strategy, including plans for new specialties, international expansion, and long-term financial targets for 2030.